A Study of Subjects Switched to Lurasidone for the Treatment of Schizophrenia or Schizoaffective Disorder
NCT ID: NCT01143090
Last Updated: 2015-06-12
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
149 participants
INTERVENTIONAL
2010-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Tolerability Study of Drug to Treat Schizophrenia
NCT00044005
The Bioequivalence Of Two Different Lurasidone Formulations In Patients
NCT01082250
Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.
NCT00790192
Lurasidone HCl A Phase 3 Study of Patients With Acute Schizophrenia
NCT00615433
Lithium Drug-Drug Interaction Study With Lurasidone HCl
NCT01074073
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Open Label
Subjects will continue on treatment with the same dose of lurasidone flexible dosing - 40 mg to 12 mg once daily taken orallay at endpoint of the D1050289 ( NCT01143077) core study.
Lurasidone HCl
40 mg Lurasidone tablets, 40 - 120 mg per day for up to 6 months
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lurasidone HCl
40 mg Lurasidone tablets, 40 - 120 mg per day for up to 6 months
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Subject has a body mass index (BMI) greater than 40 or less than 18 kg/m2 (see Appendix 3 for BMI determination).
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sumitomo Pharma America, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director, MD
Role: STUDY_DIRECTOR
Sumitomo Pharma America, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
K and S Professional Research Services
Little Rock, Arkansas, United States
Synergy Clinical Research of Escondido
Escondido, California, United States
Collaborative Neuroscience Network, Inc.
Garden Grove, California, United States
Pacific Research Partners, LLC
Oakland, California, United States
California Clinical Trials
Paramount, California, United States
Pasadena Research Institute
Pasadena, California, United States
California Neuropsychopharmacology Clinical Research Institute (CNRI), LLC
Pico Rivera, California, United States
California Neuropsychopharmacology Clinical Research Institute (CNRI)
San Diego, California, United States
University of California San Diego Medical Center
San Diego, California, United States
Collaborative Neuroscience Network, South Bay
Torrance, California, United States
Western Affiliated Research Institute
Denver, Colorado, United States
Comprehensive NeuroScience, Inc.
Atlanta, Georgia, United States
Medical College of Georgia
Augusta, Georgia, United States
University of Illinois at Chicago
Chicago, Illinois, United States
Lake Charles Clinical Trials
Lake Charles, Louisiana, United States
St. Charles Psychiatric Associates - Midwest Research
Saint Charles, Missouri, United States
Neurobehavioral Research, Inc.
Cedarhurst, New York, United States
The Zucker Hillside Hospital
Glen Oaks, New York, United States
Duke University Dept. of Psychiatry
Durham, North Carolina, United States
Wake Forest University Baptist Medical Center
Winston-Salem, North Carolina, United States
CRI Worldwide - Kirkbride Center
Philadelphia, Pennsylvania, United States
FutureSearch Clinical Trials, LP
Austin, Texas, United States
FutureSearch Trials of Dallas
Dallas, Texas, United States
Pillar Clinical Research, LLC
Dallas, Texas, United States
University of Texas Southwestern Medical Center
Dallas, Texas, United States
Wharton Research Center
Wharton, Texas, United States
University of Utah School of Medicine
Salt Lake City, Utah, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Citrome L, Weiden PJ, McEvoy JP, Correll CU, Cucchiaro J, Hsu J, Loebel A. Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study. CNS Spectr. 2014 Aug;19(4):330-9. doi: 10.1017/S109285291300093X. Epub 2013 Dec 16.
Awad G, Ng-Mak D, Rajagopalan K, Hsu J, Pikalov A, Loebel A. Long-term health-related quality of life improvements among patients treated with lurasidone: results from the open-label extension of a switch trial in schizophrenia. BMC Psychiatry. 2016 Jun 1;16:176. doi: 10.1186/s12888-016-0879-5.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D1050290
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.